Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on February 9, 2026, and the Company’s common stock will open for trading on The Nasdaq Global Market on February 9, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 207.
Peripheral artery disease is steadily moving from a niche cardiovascular concern into one of the most investable intersections of aging demographics, diabetes prevalence, and technology-enabled care. With more than 8.5 million Americans affected and global incidence rising sharply, PAD has become a multibillion-dollar problem hiding in plain sight. Market estimates now place the PAD treatment and monitoring space at roughly $6 billion in 2026, with projections pushing beyond $8.5 billion by 2031 as healthcare systems shift toward earlier detection, fewer repeat procedures, and data-driven longitudinal care.
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union
Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is gaining investor attention as a next-generation biopharmaceutical company developing advanced immune-strengthening therapeutics for some of the world’s most critical diseases, including HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes .
The autonomous vehicle revolution has officially moved beyond concept and into real-world deployment. In major U.S. cities including Phoenix, San Francisco, Los Angeles, and Austin, fully driverless robotaxi fleets operated by Waymo, Cruise, and Tesla are already transforming urban mobility.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
